• July 18, 2021

How do you treat your chronic pain?

The first patient of a new drug that treats pain in patients with multiple sclerosis is on trial in Europe.

The University of Oxford’s Centre for Regenerative Medicine is testing rx pharma’s first new drug in the treatment of multiple sclerosis, called MSX, for patients with a range of symptoms.

The drug, called rx-150, is the first to target a protein in the immune system called T-cell proliferation.

It was developed by Oxford’s Department of Biomedical Engineering and the UK’s Royal College of Surgeons, which is part of Oxford University’s Medical Research Council.

“This is a very exciting drug because it’s the first drug that’s targeting the target that causes the most pain in the world,” Professor Richard Wollaston, the University of Cambridge’s director of regenerative medicine, said.

“It’s not only going to reduce the amount of pain, but it’s also going to improve the quality of life.”

The University has been working with Oxford University Medical School, the UK Centre for Bioengineering and the US company GlaxoSmithKline.

In addition to the Oxford team, Oxford University researchers have also contributed to the trial.

The trial is being run at the University Hospitals of St Thomas in London.

Dr Wollaston said rx is the only new pain treatment in the human body.

“You get a very low level of pain in people with MS, and it’s really important to treat that,” he said.

“It’s very rare that you get a drug that is able to actually address pain.”‘

We want to get back to the future’The drug was developed in collaboration with the University’s Centre of Regenerative Medical Sciences and the University Hospital St Thomas, Oxford.

“The main purpose of the MSX drug is to get the cells to be more receptive to other T-cells and they’re doing that by releasing a protein called TNF-α, and TNF is what makes the T-helper cells, which are the immune cells, more receptive,” Dr Wollasons team said.

The Oxford team has also created an artificial immune system that can be used in patients in their 80s and 90s who have not yet been given the drug.

“They can be older people, or people with chronic pain who are struggling with MS or people who are having difficulties,” Dr William MacLeod, an associate professor in the School of Medicine, said of the patients in the trial, which started earlier this year.

“We want them to be able to feel more comfortable and to be better able to work, but also to be less likely to be sick and to go to hospital.”

The Oxford trial is the latest phase of a clinical trial to see if the drug can reduce the number of MSX-related deaths in the UK.

The MSX treatment, known as rx, targets the protein called Th17 in the body.

People with MS have a mutation in this protein that causes them to develop pain in parts of their body.

The protein also appears to play a role in inflammation and immune system disease.

The UK Centre of Bioengineering, Oxford, is working to develop drugs to treat the disease.

“Our hope is that we can do some treatment with rx and then we can see whether we can prevent other people getting MSX,” Professor Wollathans team said.

“It is going to be a really exciting clinical trial.”